Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...
“While S1613 showed that anti-HER2 therapy was better tolerated and similarly efficacious to anti-EGFR therapy, the key finding is that the relative benefit of these therapies may depend on the ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
The EGFR family consists of four different members: EGFR; human epidermal growth factor receptor (HER) 2; HER3; and HER4. Upon ligand binding, these receptors can homodimerize or heterodimerize ...
Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 receptor, and lapatinib, a dual reversible EGFR/HER2 TKI, are indicated for the treatment of HER2 ...
Sunvozertinib inhibits EGFR and HER2, potentially leading to tumor regression and is being tested in first-line settings in the WU-KONG28 trial. Priority review aims for faster FDA action on drugs ...
Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.
Previously, EGFR mutation-positive NSCLC patients relied ... The recommendation covers Lynparza’s use in patients with HER2-negative, locally advanced or metastatic breast cancer who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback